Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

888
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
888
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Regulation of Food Intake01:30

Regulation of Food Intake

3.2K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
3.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

957
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
957

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in HbA1c With Glucagon-Like Peptide-1 Receptor Agonist Therapy Alone and Followed by Initiation of Continuous Glucose Monitoring: A Retrospective Analysis of U.S. Medical Claims Data.

Journal of diabetes science and technology·2026
Same author

Use of administrative data for evaluating trends in medically-attended Lyme disease, Manitoba, Canada, 2010-2021.

PloS one·2026
Same author

The acute effects of Zensera™ (<i>Melissa officinalis L.</i>) extract on mood and cognitive performance during cognitive overload: a randomised placebo-controlled, double-blind study in healthy young adults with moderate subjective stress.

Therapeutic advances in psychopharmacology·2026
Same author

Safety assessment and gastrointestinal tolerance of a novel highly bioavailable turmeric extract formulation: A randomised, double-blind, placebo controlled clinical trial.

Toxicology reports·2025
Same author

Normal echocardiographic and electrocardiographic indices in young female athletes: a meta-analysis across sex, types of sports, races, and ethnicities.

European journal of preventive cardiology·2025
Same author

A randomized, placebo-controlled, crossover clinical trial to evaluate the effect of a turmeric formulation on muscle soreness and function recovery in moderately active adults.

Journal of the International Society of Sports Nutrition·2025
Same journal

Microbial-derived polyphenol metabolites and the gut microbiota: A scoping review of clinical studies.

The Journal of nutrition·2026
Same journal

Hesperidin as an Emerging Nutraceutical in Modern Health and Preventive Medicine: A Narrative Review.

The Journal of nutrition·2026
Same journal

Short-Chain Fatty Acids in Livestock and Aquatic Animals: Metabolic Divergence, Physiological Functions, and Product Development.

The Journal of nutrition·2026
Same journal

Immunomodulatory properties of choline and its dietary forms throughout the lifespan.

The Journal of nutrition·2026
Same journal

Oat-rich low-gluten diet modulates plasma short-chain fatty acids without significant changes in fecal microbiome or inflammatory markers - a randomized clinical trial in people with cardiometabolic risk.

The Journal of nutrition·2026
Same journal

Diet and Cognitive Function in Aging: An Individual Participant Data Meta-Analysis from Eight Cohorts in Europe and the United States.

The Journal of nutrition·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.6K

α-Galacto-oligosaccharides Dose-Dependently Reduce Appetite and Decrease Inflammation in Overweight Adults.

Fanny B Morel1, Qiuping Dai2, Jiayi Ni3

  • 1Olygose S.A.S., Compiègne, France; fanny.morel@olygose.com.

The Journal of Nutrition
|July 17, 2015
PubMed
Summary
This summary is machine-generated.

Alpha-galactooligosaccharides (α-GOSs) supplementation dose-dependently reduced appetite and food intake in overweight adults. This dietary fiber intake also lowered inflammatory markers, suggesting potential for weight management and metabolic health improvement.

Keywords:
alpha-galacto-oligosaccharidesappetitefibersfood intakeinflammation

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.6K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

783

Related Experiment Videos

Last Updated: Apr 7, 2026

One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.6K
Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.6K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

783

Area of Science:

  • Nutrition Science
  • Gastroenterology
  • Metabolic Health

Background:

  • Dietary fibers are linked to reduced appetite and energy intake.
  • Limited data exist on non-viscous fibers, like alpha-galactooligosaccharides (α-GOSs), and their effects via colonic fermentation.

Purpose of the Study:

  • To investigate if α-GOSs, fermentable soluble fibers from legumes, can decrease appetite, food intake, and inflammation in overweight individuals.
  • To assess dose-dependent effects and the impact of α-GOS composition.

Main Methods:

  • Two double-blind, randomized, placebo-controlled trials involving 88 overweight adults.
  • Supplementation with varying doses of α-GOSs (6, 12, 18 g/d) or a control for 14 days.
  • Evaluation of appetite scores, food intake (test meal and 24-h recall), and inflammatory markers (LPS, CRP).

Main Results:

  • α-GOS intake significantly increased satiety scores in a dose-dependent manner.
  • Energy intake during a test meal and overall daily intake (lunch, dinner) were dose-dependently reduced with α-GOSs.
  • Plasma lipopolysaccharide (LPS) and C-reactive protein (CRP) levels were significantly reduced by α-GOSs.

Conclusions:

  • 14-day α-GOSs consumption dose-dependently reduced appetite, food intake, and inflammation in overweight adults.
  • α-GOS composition did not affect outcomes, indicating efficacy across different formulations.
  • α-GOSs show promise for promoting long-term weight loss and mitigating metabolic disorders.